Lurasidone a new atypical antipsychotic

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Lurasidone is a new atypical antipsychotic that is effective for short- and long-term treatment of patients with schizophrenia. It joins ziprasidone and aripiprazole as 'metabolically friendly' treatments but, unlike ziprasidone, has a low risk of causing QT prolongation. Possible side effects include akathisia and parkinsonism.

Original languageEnglish
Pages (from-to)56-57
Number of pages2
JournalMedicine Today
Volume17
Issue number9
Publication statusPublished - 1 Sep 2016

Cite this

@article{3996429bc88e476f8a22e4cef1f1a6c6,
title = "Lurasidone a new atypical antipsychotic",
abstract = "Lurasidone is a new atypical antipsychotic that is effective for short- and long-term treatment of patients with schizophrenia. It joins ziprasidone and aripiprazole as 'metabolically friendly' treatments but, unlike ziprasidone, has a low risk of causing QT prolongation. Possible side effects include akathisia and parkinsonism.",
author = "Nicholas Keks and Judy Hope",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "17",
pages = "56--57",
journal = "Medicine Today",
issn = "1443-430X",
publisher = "Medicine Today",
number = "9",

}

Lurasidone a new atypical antipsychotic. / Keks, Nicholas; Hope, Judy.

In: Medicine Today, Vol. 17, No. 9, 01.09.2016, p. 56-57.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Lurasidone a new atypical antipsychotic

AU - Keks, Nicholas

AU - Hope, Judy

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Lurasidone is a new atypical antipsychotic that is effective for short- and long-term treatment of patients with schizophrenia. It joins ziprasidone and aripiprazole as 'metabolically friendly' treatments but, unlike ziprasidone, has a low risk of causing QT prolongation. Possible side effects include akathisia and parkinsonism.

AB - Lurasidone is a new atypical antipsychotic that is effective for short- and long-term treatment of patients with schizophrenia. It joins ziprasidone and aripiprazole as 'metabolically friendly' treatments but, unlike ziprasidone, has a low risk of causing QT prolongation. Possible side effects include akathisia and parkinsonism.

UR - http://www.scopus.com/inward/record.url?scp=84990935088&partnerID=8YFLogxK

M3 - Review Article

VL - 17

SP - 56

EP - 57

JO - Medicine Today

JF - Medicine Today

SN - 1443-430X

IS - 9

ER -